# US 2023/0054326 A1 · Probiotic composition for treating rapid eye movement sleep behavior disorder, formulation and use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054326 A1
- Document ID: US20230054326A1
- Status: Published application
- Kind: A1
- Application number: 17/938,671
- Filed: 2022-10-06
- Published: 2023-02-23
- Earliest claimed: 2020-04-10
- Assignees: Beijing Friendship Hospital Affiliated To Capital Medical University
- Applicants: Beijing Friendship Hospital Affiliated To Capital Medical University
- Inventors: Houzhen TUO; Yitong DU; Xiaojiao XU; Yue LI; Mingkai ZHANG; Ying CUI; Yun XUE; Dan GAO; Ting GAO; Zhi SHENG
- Web page: https://patentgrep.com/patent/US20230054326A1

## CPC

- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 35/745: Bifidobacteria
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/20: Hypnotics; Sedatives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A probiotic composition for treating rapid eye movement sleep behavior disorder, is prepared from Bacillus licheniformis, Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis, and pharmaceutically acceptable adjuvants. The probiotic composition can improve the symptoms of rapid eye movement sleep behavior disorder of a patient, improve RBD symptoms of idiopathic RBD patients and PD patients, improve the motor symptoms and reduce the daily levodopa equivalent dose in PD patients.

## Claims

### Claim 1

A probiotic composition for treating rapid eye movement sleep behavior disorder, comprising Bacillus licheniformis, Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis.

### Claim 2 (depends on 1)

The probiotic composition for treating rapid eye movement sleep behavior disorder according to claim 1, further comprising adjuvants.

### Claim 3 (depends on 1)

The probiotic composition for treating rapid eye movement sleep behavior disorder according to claim 1, wherein
the viable count of Bacillus licheniformis in the probiotic composition is not less than 1×107 CFU/g.

### Claim 4 (depends on 1)

The probiotic composition for treating rapid eye movement sleep behavior disorder according to claim 1, wherein
the viable count of Bifidobacterium longum in the probiotic composition is not less than 1×107 CFU/g.

### Claim 5 (depends on 1)

The probiotic composition for treating rapid eye movement sleep behavior disorder according to claim 1, wherein
the viable count of Lactobacillus acidophilus in the probiotic composition is not less than 1×107 CFU/g.

### Claim 6 (depends on 1)

The probiotic composition for treating rapid eye movement sleep behavior disorder according to claim 1, wherein
the viable count of Enterococcus faecalis in the probiotic composition is not less than 1×107 CFU/g.

### Claim 7 (depends on 1)

The probiotic composition for treating rapid eye movement sleep behavior disorder according to claim 1, wherein the probiotic composition is obtained by the following steps:
preparing the probiotic composition according to claim 1 as a lyophilized powder and then mixing.

### Claim 8 (depends on 1)

The probiotic composition for treating rapid eye movement sleep behavior disorder according to claim 1, wherein
the rapid eye movement sleep behavior disorder comprises idiopathic rapid eye movement sleep behavior disorder and/or rapid eye movement sleep behavior disorder in Parkinson's disease.

### Claim 9

A method for treating rapid eye movement sleep behavior disorder by administration of a probiotic composition, wherein
the probiotic composition is prepared from Bacillus licheniformis, Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis as well as adjuvants.

### Claim 10 (depends on 9)

The method according to claim 9, wherein
the viable count of Bacillus licheniformis in the probiotic composition is not less than 1×107 CFU/g.

### Claim 11 (depends on 9)

The method according to claim 9, wherein
the viable count of Bifidobacterium longum in the probiotic composition is not less than 1×107 CFU/g.

### Claim 12 (depends on 9)

The method according to claim 9, wherein
the viable count of Lactobacillus acidophilus in the probiotic composition is not less than 1×107 CFU/g.

### Claim 13 (depends on 9)

The method according to claim 9, wherein
the viable count of Enterococcus faecalis in the probiotic composition is not less than 1×107 CFU/g.

### Claim 14 (depends on 9)

The method according to claim 9, wherein
the probiotic composition can be prepared as probiotic formulations, drugs, nutraceuticals and/or food products.

### Claim 15

A probiotic formulation for treating rapid eye movement sleep behavior disorder,
comprising Bacillus licheniformis, Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis as well as adjuvants used for preparing the probiotic composition as a probiotic dosage form.

### Claim 16 (depends on 15)

The probiotic formulation according to claim 15, wherein
the viable count of Bacillus licheniformis in the probiotic composition is not less than 1×107 CFU/g;
the viable count of Bifidobacterium longum in the probiotic composition is not less than 1×107 CFU/g;
the viable count of Lactobacillus acidophilus in the probiotic composition is not less than 1×107 CFU/g; and
the viable count of Enterococcus faecalis in the probiotic composition is not less than 1×107 CFU/g.

### Claim 17 (depends on 15)

The probiotic formulation according to claim 15, wherein the probiotic formulation is obtained by the following steps:
(1) preparing each bacterial powder: preparing dried bacterial powder of the Bacillus licheniformis, Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis, respectively; and
(2) mixing each dried bacterial powder obtained in step (1) with the adjuvants, forming and dispensing.

### Claim 18 (depends on 15)

A method for treating rapid eye movement sleep behavior disorder by administration of the probiotic formulation according to claim 15.

### Claim 19

A food composition or supplement comprising a probiotic composition, wherein the probiotic composition is prepared from Bacillus licheniformis, Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis, as well as adjuvants.

### Claim 20 (depends on 19)

The food composition or supplement according to claim 19, wherein
the viable count of Bacillus licheniformis in the probiotic composition is not less than 1×107 CFU/g;
the viable count of Bifidobacterium longum in the probiotic composition is not less than 1×107 CFU/g;
the viable count of Lactobacillus acidophilus in the probiotic composition is not less than 1×107 CFU/g; and
the viable count of Enterococcus faecalis in the probiotic composition is not less than 1×107 CFU/g.
